Showing results (71-80 of 85) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancerMarkus M Borner, Daniel Dietrich, Roger Stupp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich, Grant A McArthur, George D Demetri, et al.Blood|July 17, 2004
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsSusan Branford, Zbigniew Rudzki, Ian Parkinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupRichard Herrmann, György Bodoky, Thomas Ruhstaller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerDavid Cunningham, Ian Chau, Deborah D Stocken, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert, Jeremy Franklin, Hans Theodor Eich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2003
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study GroupAndreas Engert, Petra Schiller, Andreas Josting, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.Pageof 9